RT112-Gr cells were left untreated or were treated with 45nM Gemcitabine (GEM), RNAi-mediated Knockdown of RRM1 and RRM2 in RT112-Gr bladder cancer cells were left untreated or were treated with 45nM Gemcitabine (GEM). This evidence concerns the gene RRM2 and urinary bladder cancer.